EMD Lexigen Research Center

EMD Lexigen Research Center was a specialized biotechnology unit of EMD Serono (Merck KGaA) focused on the development of immunocytokines for oncology. Originally founded as Lexigen Pharmaceuticals, the center pioneered the fusion of tumor-targeting monoclonal antibodies with potent cytokines like Interleukin-2 and Interleukin-12 to enhance immune responses within the tumor microenvironment. Its research contributed significantly to the Merck KGaA oncology pipeline, particularly through candidates like NHS-IL12 and other targeted immunotherapies. The facility, located in Billerica, Massachusetts, served as a hub for protein engineering and early-stage clinical development before being fully integrated into the parent company's global R&D structure.